Intersect ENT Announces Positive Results From Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients

Published: Sep 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MENLO PARK, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and their patients, today reported findings from a prospective U.S. multi-center pilot study to evaluate the feasibility, safety and efficacy of the company’s newest steroid delivery implant for patients suffering from the debilitating symptoms of chronic sinusitis. Results were presented at the Annual American Rhinologic Society Meeting in Vancouver, Canada, and were recognized by the society with the Cottle Award for Best Clinical Science Research. \

Help employers find you! Check out all the jobs and post your resume.

Back to news